Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
- 02/18/2025
|
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
- BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida.
- 02/13/2025
|
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST.
- 01/07/2025
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 12/16/2024
|
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
- Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif.
- 12/16/2024
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/15/2024
|
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
- Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025
- 11/14/2024
|
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
- BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT.
- 11/13/2024
|
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
- Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD).
- 10/21/2024
|
Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)
- On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104.
- 10/03/2024
|
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
- Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company's pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver.
- 08/17/2024
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/16/2024
|
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/16/2024
|
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
- Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation
- 07/11/2024
|
Are Medical Stocks Lagging Annexon (ANNX) This Year?
- Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
- 06/28/2024
|
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
- After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 06/27/2024
|
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
- ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints
- 06/25/2024
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 14, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/17/2024
|
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
- Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
- 06/07/2024
|
Annexon Announces Pricing of $125 Million Underwritten Public Offering
- BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.
- 06/05/2024
|
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
- Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
- 06/05/2024
|
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
- The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 06/05/2024
|
Annexon Announces Proposed Public Offering of Common Stock
- BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $18.750 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
- 06/04/2024
|
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
- Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025. If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025.
- 06/04/2024
|
Annexon's neurological disorder drug meets main goal of late-stage study
- Annexon Inc said on Tuesday its experimental drug to treat a rare neurological disorder met the main goal of a late-stage trial.
- 06/04/2024
|
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
- BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m.
- 06/03/2024
|
Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 05/20/2024
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/16/2024
|
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
- Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in GA Expected in mid-2024 Clinical Proof of Concept (POC) Data for ANX1502, an Oral Classical Pathway Inhibitor for Chronic Autoimmune Conditions, on Track for Second Half of 2024 Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $264.9 Million as of March 31, 2024, and Anticipated Runway into mid-2026 BRISBANE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported first quarter 2024 financial results.
- 05/13/2024
|
Annexon Biosciences to Present at the Bank of America Health Care Conference
- BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Bank of America Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT.
- 05/09/2024
|
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
- ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings
- 05/07/2024
|
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
- Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation
- 05/01/2024
|
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
- Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 04/25/2024
|
Are Medical Stocks Lagging Annexon (ANNX) This Year?
- Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
- 04/17/2024
|
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/16/2024
|
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
- In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.
- 04/10/2024
|
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 11:00 a.m. ET.
- 04/03/2024
|
What Makes Annexon (ANNX) a New Buy Stock
- Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/01/2024
|
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 04/01/2024
|
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
- Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primary Outcome Measure Clinical Proof-of-Concept Data with ANX1502 Oral Inhibitor of the Classical Pathway Expected in Second Half of 2024 Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $260 Million as of December 31, 2023, and Anticipated Runway into mid-2026 BRISBANE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.
- 03/26/2024
|
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/18/2024
|
Why Annexon (ANNX) Might Surprise This Earnings Season
- Annexon (ANNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/14/2024
|
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
- BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a corporate panel discussion focused on Ophthalmology, at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:10 p.m. ET in Boston, MA.
- 02/27/2024
|
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach
- Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, Professor Emeritus of Johns Hopkins University School of Medicine BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET.
- 02/21/2024
|
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/20/2024
|
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
- Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.
- 01/18/2024
|
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
- Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
- 01/17/2024
|
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
- ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.
- 01/07/2024
|
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.
- 12/27/2023
|
Annexon: ANX007 Advances Forward With Stellar Endpoint
- Alignment with FDA reached to have phase 3 ARROW study use Best Corrected Visual Acuity ≥ 15-Letter Loss as the primary endpoint; Significance of this could mean competitive advantage. A sham-controlled trial, known as ARCHER II expected to begin in mid-2024, could provide a quicker pathway towards European regulatory approval. The prior phase 2 ARCHER study showed that patients given ANX-007 achieved the endpoint of protection of vision loss measured by BCVA compared to baseline.
- 12/23/2023
|
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
- BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.
- 09/19/2023
|
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
- Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 09/08/2023
|
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
- Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET
- 07/24/2023
|
Annexon: Mixed Results, Overly Strong Market Reaction
- ANNX produced mixed results from its GA program. While the primary endpoint was not met, an important functional endpoint saw success. However, the market reaction was drastic, and perhaps too drastic.
- 07/14/2023
|
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
- Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
- 05/30/2023
|
Why Shares of Annexon Are Plummeting Thursday
- Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.
- 05/25/2023
|
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
- Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.
- 05/21/2023
|
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
- Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. The Active ETF portfolio continues with YTD gains at +14.2%.
- 05/14/2023
|
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
- April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.
- 04/23/2023
|
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
- BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.
- 01/04/2023
|
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
- Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain. The 28 patients were dosed for six months and followed for three more.
- 06/07/2022
|
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
- BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.
- 06/02/2022
|
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
- BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.
- 06/01/2022
|
Annexon Biosciences to Participate in Upcoming May Investor Conferences
- BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:
- 05/05/2022
|
What Are Penny Stocks? What You Need to Know and 3 to Watch
- Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/20/2022
|
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022
- BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology (AAN) Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022.
- 03/03/2022
|
BMEZ: Buy Low, Hold For The Distribution And Rebound
- BMEZ: Buy Low, Hold For The Distribution And Rebound
- 02/07/2022
|
Why Annexon Biosciences Stock Plummeted 34% Today
- Investors were unimpressed by the biotech's latest clinical update.
- 01/05/2022
|
Annexon Stock (ANNX): Why The Price Substantially Dropped Today
- The stock price of Annexon Inc (NASDAQ: ANNX) fell by over 35% during intraday trading today. This is why it happened.
- 01/05/2022
|
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
- Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period. Annexon is developing ANX005, its lead monoclonal antibody candidate, for a range of complement-mediated disorders, including HD.
- 01/05/2022
|
Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
- BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET.
- 01/04/2022
|
Annexon (ANNX) Stock: $40 Price Target From H.C. Wainwright
- The shares of Annexon Inc (NASDAQ: ANNX) have received a $40 price target from H.C. Wainwright.
- 11/30/2021
|
Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D.
- – Dr. Ted Yednock's appointment enhances Annexon's commitment to scientific innovation and pursuit of future programs –
- 10/04/2021
|
Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
- CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that Douglas Love, Esq., President & Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 12:40 p.m. ET.
- 09/23/2021
|
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
- CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise. Annexon's R&D event will include presentations from the executive team as well as prominent key opinion leaders.
- 09/20/2021
|
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
- – Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –
- 08/16/2021
|
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
- Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis
- 07/22/2021
|
Annexon to Present at the Raymond James Human Health Innovation Conference
- SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the virtual Raymond James Human Health Innovation Conference on June 23rd, 2021 at 1:20 pm EDT.
- 06/16/2021
|
Moving Average Crossover Alert: Annexon (ANNX)
- Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 05/21/2021
|
Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Virtual Healthcare Conference on May 12, 2021 at 11:45 am EDT.
- 05/05/2021
|
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
- Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) or dry AMD, can lead to blindness caused by damaged and dying retinal cells.
- 03/01/2021
|
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy
- SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) or dry AMD, can lead to blindness caused by damaged and dying retinal cells. Currently, there are no approved treatment options to prevent onset or progression of GA.
- 03/01/2021
|
Annexon Welcomes William H. Carson, M.D.
- Thomas G. Wiggans appointed Chairman Thomas G. Wiggans appointed Chairman
- 02/08/2021
|
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
- BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments.
- 01/30/2021
|
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
- U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
- 01/16/2021
|
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics
- SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today highlights recent achievements and outlines expected key 2021 milestones at the J.P. Morgan 39th Annual Healthcare Conference, held virtually.
- 01/12/2021
|
Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced that a corporate update will be presented at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 4:30pm ET.
- 01/05/2021
|
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/15/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
- 07/31/2020
|
Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer
- SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appointment of Michael Overdorf as Chief Business Officer. “I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our corporate and commercial development efforts,” said Douglas Love, Chief Executive Officer of Annexon Biosciences. “The potential for our classical complement pathway platform technology is broad and deep across a number of different therapeutic areas, and Michael will be a key member of the team driving our business development and commercial strategies.” Mr. Overdorf brings nearly 20 years of industry experience to Annexon. Prior to joining he spent 19 years at Eli Lilly and Company in various executive leadership roles, most recently in Corporate Business Development, a position he held for the last two years. Prior to that role, Mr. Overdorf led Lilly’s Corporate Strategy, led two Phase 3 autoimmune development programs, and spent a decade in multiple global commercial leadership roles. Mr. Overdorf has deep expertise across every stage of the pharmaceutical value chain, including research and development, clinical product development, commercial launch, pricing and access, corporate affairs, and sales and marketing. Prior to Lilly he was the Co-founder, Chairman and CEO of Innosight, a consulting firm focused on disruptive innovation. Mr. Overdorf holds an MBA from Harvard Business School and a BA in Economics from Wabash College.“I am delighted to join the leadership team at Annexon. With an impressive pipeline of promising C1q classical complement assets, the opportunities for Annexon are vast,” said Mr. Overdorf, Chief Business Officer of Annexon. “I look forward to helping the company leverage its platform and navigate its strategic commercial and business development options to enhance the value of the organization and reach patients in need of therapeutic alternatives.”About Annexon, Inc. Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue. For more information, visit www.annexonbio.com.Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.comAlexandra Santos asantos@wheelhouselsa.comMedia Contact: Sara Michelmore smichelmore@macbiocom.com
- 07/30/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
Annexon Announces Closing of Initial Public Offering
- SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of its initial public offering of 14,750,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock were offered by Annexon. Annexon’s common stock began trading on The Nasdaq Global Select Market on July 24, 2020, under the ticker symbol “ANNX.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Annexon, were approximately $250.8 million. In addition, Annexon has granted the underwriters a 30-day option to purchase up to an additional 2,212,500 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. J.P. Morgan, BofA Securities and Cowen are acting as joint book-running managers for the offering.Registration statements relating to the shares sold in this offering were filed with the Securities and Exchange Commission and became effective on July 23, 2020. The offering was made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmorgan.com or by telephone at (866) 803-9204; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Annexon, Inc.Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.comAlexandra Santos asantos@wheelhouselsa.comMedia Contact:Sara Michelmore smichelmore@macbiocom.com
- 07/28/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
U.S. IPO Weekly Recap: Software And SPACs Shine In A 7-IPO Week
- Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding and the largest SPAC ever Pershing Square Tontine Holdings.
- 07/25/2020
|
Stocks To Watch: Big Focus On Big Tech
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 07/25/2020
|
IPO Update: Annexon Proposes IPO Terms
- Annexon has filed to raise $150 million in an IPO of its common stock. The firm is developing treatments for autoimmune and neurodegenerative diseases.
- 07/20/2020
|
U.S. IPO Week Ahead: Software Provider Jamf Takes The Spotlight In A Diverse 4-IPO Week
- Four IPOs and one SPAC plan to raise $663 million in the week ahead, led by Jamf Holding. The IPO market is on a hot streak, and the IPO pipeline is filling up as filing activity remains high.
- 07/18/2020
|
Annexon Initiates $100 Million IPO Effort
- Annexon aims to raise $100 million in an IPO, although the final figure may differ. The firm is advancing treatments for various autoimmune and neurodegenerative disorders.
- 07/11/2020
|
La cena del año 2054
- El restaurante Leka ofrece cada mes en Fab City Hub un menú elaborado con técnicas novedosas hoy en día que serán habituales en el futuro
- 02/03/2020
|
